Mitsubishi A6M Zero

Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial

Retrieved on: 
Monday, August 29, 2022
AES, COVID-19, Technology, Safety, Research, University, Penn, A4, Real-time, U.S. Securities and Exchange Commission, GLOBE, Company, Adult, Risk, Congress, Patient, Neurotoxicity, Glomerulonephritis, CRS, Immunity, Incidence, Biopsy, Pemphigus, Immunoglobulin therapy, MPV, Mitsubishi A6M Zero, Annual report, Cyclophosphamide, Security (finance), Poster, Infrared spectroscopy correlation table, Form 10-K, Degenerative disease, CAR, Haemophilia, Disease, LinkedIn, Perelman School of Medicine at the University of Pennsylvania, Cytokine release syndrome, Private Securities Litigation Reform Act, Health, European Academy of Allergy and Clinical Immunology, Infection, MuSK protein, ELISA, CEST, University of Pennsylvania, Pharmaceutical industry, A5, Venereology, Cabaletta, Dermatology

The DesCAARTes Phase 1 trial is an open-label, dose escalation, multi-center study of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV).

Key Points: 
  • The DesCAARTes Phase 1 trial is an open-label, dose escalation, multi-center study of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV).
  • "The totality of the data generated to date from the DesCAARTes trial has provided important insights that have guided our efforts to enhance in vivo DSG3-CAART exposure.
  • The University of Pennsylvania may also receive future financial benefit under licenses it has granted to Cabaletta Bio.
  • All information in this press release is as of the date of the release, and Cabaletta undertakes no duty to update this information unless required by law.

Cabaletta Bio Presents Updated Interim DesCAARTes™ Trial Phase 1 Data at the ASGCT 25th Annual Meeting

Retrieved on: 
Wednesday, May 18, 2022
U.S. Securities and Exchange Commission, Phenotype, Risk, Company, Annual general meeting, Private Securities Litigation Reform Act, Toxicity, Anti-CD19 immunotoxin, The Retreat, Glomerulonephritis, Annual report, AES, A1, Incidence, Pemphigus, Degenerative disease, Patient, Form 10-K, Real-time, Society, Annexin A5 affinity assay, COVID-19, Data, Cytokine release syndrome, Adult, ELISA, Gene, FDA, Program, A5, Safety, CRS, Haemophilia, Biopsy, LinkedIn, Infrared spectroscopy correlation table, Cell, CART, MuSK protein, Neurotoxicity, Mitsubishi A6M Zero, Security (finance), GLOBE, Pharmaceutical industry, Vaccine, A3, A4, Cabaletta, MPV

These data continue to support the planned dose escalation in this trial and our conviction in the potential of this program.

Key Points: 
  • These data continue to support the planned dose escalation in this trial and our conviction in the potential of this program.
  • Cabalettas DesCAARTes Phase 1 trial is an open-label, dose escalation, multi-center study of DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV).
  • The trial is currently in cohort A5 (5.0 to 7.5 billion cells) and is being conducted across multiple clinical sites throughout the United States.
  • The updated interim DesCAARTes trial Phase 1 data included 12 treated subjects, four cohorts with three patients per cohort; nine having completed six months follow up after DSG3-CAART infusion.

Level 10 Construction Achieves 7 Million Work Hours With Zero Lost Time

Retrieved on: 
Friday, February 12, 2021
Silicon Valley, Sunnyvale, California, Mitsubishi A6M Zero, Geography of California, Aircraft, Geography of the United States

SUNNYVALE, Calif., Feb. 12, 2021 /PRNewswire/ -- Exactly one year ago today, Level 10 Construction announced that it had completed 6 million work hours with zero lost-time incidents.

Key Points: 
  • SUNNYVALE, Calif., Feb. 12, 2021 /PRNewswire/ -- Exactly one year ago today, Level 10 Construction announced that it had completed 6 million work hours with zero lost-time incidents.
  • Today, Level 10 announces that in a year's time the company has completed another million work hours with zero lost-time incidents, bringing its total work hours with zero lost-time incidents to 7 million.
  • Level 10 in 2020 completed its 7thfull year with zero lost-time injuries, and just last month surpassed 7 million hours with zero lost-time injuries.
  • Level 10 Construction is a full-service general contractor with offices throughout California, including Sunnyvale, San Francisco and San Diego.

National Geographic Builds on Power of Its Diverse Slate With Season Pickups of Franchise Series BRAIN GAMES, RUNNING WILD WITH BEAR GRYLLS and LIFE BELOW ZERO

Retrieved on: 
Saturday, January 18, 2020
TV and Radio, Celebrity, Entertainment, Film & Motion Pictures, Television, American television series, Running Wild with Bear Grylls, Bear Grylls, Gordon Ramsay, National Geographic, Mitsubishi A6M Zero, Life Below Zero, Jude and Zero, Below Zero

It was also announced that the second season of GORDON RAMSAY: UNCHARTED will premiere on Sunday, May 10, at 10/9c on National Geographic.

Key Points: 
  • It was also announced that the second season of GORDON RAMSAY: UNCHARTED will premiere on Sunday, May 10, at 10/9c on National Geographic.
  • Finding a new home on National Geographic this season, the wildly popular hit series RUNNING WILD WITH BEAR GRYLLS garners an original season pickup ahead of its season finale.
  • The three-series commitment deal also includes two additional seasons of Life Below Zero and an additional season of Life Below Zero: Port Protection.
  • LIFE BELOW ZERO, LIFE BELOW ZERO: PORT PROTECTION and LIFE BELOW ZERO: NEXT GENERATION are produced by BBC Studios for National Geographic.

BraveHearts’ “Trail to Zero” Rides in to New York, D.C. and Chicago

Retrieved on: 
Monday, July 29, 2019
Health, Philanthropy, Mental health, Other Philanthropy, Other Defense, Defense, Fund Raising, Foundation, Bravehearts, Nas, Mitsubishi A6M Zero, New York City, Aircraft, Aviation, Cities in the United States

To shed light on the growing epidemic of veteran suicide, BraveHearts the leading equine rehabilitation program for veterans in the nationwill embark on its third annual Trail to Zero ride in New York, Washington D.C. and Chicago.

Key Points: 
  • To shed light on the growing epidemic of veteran suicide, BraveHearts the leading equine rehabilitation program for veterans in the nationwill embark on its third annual Trail to Zero ride in New York, Washington D.C. and Chicago.
  • Trail to Zero was developed after countless conversations with veterans about the intensifying suicide pandemic tragically affecting so many, said Meggan Hill-McQueeney, President/COO, BraveHearts.
  • Trail to Zero is supported by the NYPD Mounted Unit, US Park Police Mounted Horse Unit and the Chicago Mounted Unit.
  • Rides will take place in September, which is National Suicide Prevention Awareness Month, in Washington, D.C. (September 7); New York City (September 14); and Chicago (September 28).